Lee Boyling, BSc (Hons)

Head of In Vitro/Ex vivo Study Direction
Alnwick, UK
lee.boyling@Covance.com

Key Roles and Responsibilities

- Management of team conducting drug metabolism, exploratory bioanalysis and *in vitro* biochemical assays
- Member of Global Metabolism Team
- Member of Alnwick Safety Assessment *In Vivo* Study Director team

Areas of Expertise

- **Drug Metabolism**
  - Biotransformation
  - Design, conduct and interpretation of metabolism studies
  - Support of investigative toxicology studies
- **Bioanalysis**
  - Conduct of exploratory LC-MS bioanalysis
  - Study Director for GLP Bioanalysis
- **Drug Development**
  - Wide experience from entry into development up to Human AME

Professional Highlights

- More than 20 years experience within the pharmaceutical industry
- Joined Sterling Winthrop (latterly sanofi-aventis) in 1992 as a scientist within Drug Metabolism, Study Directing *in vitro* CYP activity assays
- By 1996 progressed to study directing nonclinical *in vivo* mass balance studies
- In 2000 changed to Clinical Metabolism which included working alongside Clinical Pharmacology to organize human AME studies
- In 2004 was lead scientist responsible for development of LC-MS metabolomics platform and in 2006 was Company Representative on COMET2 consortium
- Following acquisition of Alnwick site by Covance in November 2010, became Head of Metabolism at Alnwick in June 2011
- In November 2014 became Head of *In Vitro/Ex vivo* Study Direction formed by merging Alnwick Drug Metabolism and Molecular Cellular Toxicology groups
- Lecturer on external course (UK Drug Metabolism Discussion Group Fundamentals Training Course)

Education

- **BSc, Applied Biology**
  University of Hertfordshire

The Americas + 1.888.COVANCE + 1.609.452.4440
Europe/Africa + 00.800.2682.2682
Asia Pacific + 800.6568.3000

11/14
© Copyright 2014 Covance Inc.

COVANCE®
SOLUTIONS MADE REAL™